Posts With Tag Multiple Sclerosis

Explore Biogen Inc.'s Q2 2025 financial highlights, including revenue growth, R&D investments, and emerging challenges. A must-read for investors focused on biopharmaceutical trends.

Tiziana Life Sciences LTD's Form 6-K reveals progress in their ISPPEA program for treating non-active secondary progressive MS, with promising patient outcomes.

Discover Sanofi's latest Form 6-K, detailing FDA designations and promising study results for Tolebrutinib and Duvakitug, crucial for investors and stakeholders.